{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:46:35Z","timestamp":1794613595297,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The CRISPR system has revolutionized cancer gene therapy, offering unparalleled precision in genetic manipulation for targeted oncogene disruption, mutation correction, and immune system modulation. This breakthrough tool has demonstrated remarkable potential in overcoming drug resistance, enhancing chemotherapy sensitivity, and improving immunotherapy strategies such as CRISPR-engineered CAR-T cells. Additionally, oncolytic virus-mediated CRISPR delivery has emerged as a novel approach for tumor-specific gene editing, minimizing off-target effects. The rapid transition of CRISPR-based cancer therapeutics from preclinical research to clinical trials underscores its therapeutic potential. This review explores the latest advancements in CRISPR applications for cancer therapy, including gene knockout, base editing for mutation correction, and integration with immune and viral therapies. Despite significant progress, challenges such as off-target effects, immune responses, and delivery limitations remain key hurdles. We discuss current strategies to enhance CRISPR safety and efficacy, emphasizing its potential for personalized cancer treatment.<\/jats:p>","DOI":"10.1038\/s41417-025-00959-9","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:35:37Z","timestamp":1758202537000},"page":"1293-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine"],"prefix":"10.1038","volume":"32","author":[{"given":"Hyeonjeong","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1476-5429","authenticated-orcid":false,"given":"Taeyoung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"959_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10:1367\u2013401.","journal-title":"Genes Dis"},{"key":"959_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition. Cancer Discov. 2014;4:61\u20138.","journal-title":"Cancer Discov"},{"key":"959_CR3","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","volume":"31","author":"J Mazi\u00e8res","year":"2013","unstructured":"Mazi\u00e8res J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31:1997\u20132003.","journal-title":"J Clin Oncol"},{"key":"959_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","volume":"22","author":"C Krepler","year":"2016","unstructured":"Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin Cancer Res. 2016;22:1592\u2013602.","journal-title":"Clin Cancer Res"},{"key":"959_CR5","first-page":"634","volume":"3","author":"IA Cree","year":"2002","unstructured":"Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr Opin Investig Drugs. 2002;3:634\u201340.","journal-title":"Curr Opin Investig Drugs"},{"key":"959_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1099\/mic.0.27437-0","volume":"151","author":"C Pourcel","year":"2005","unstructured":"Pourcel C, Salvignol G, Vergnaud G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology. 2005;151:653\u201363.","journal-title":"Microbiology"},{"key":"959_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","volume":"60","author":"FJ Mojica","year":"2005","unstructured":"Mojica FJ, D\u00edez-Villase\u00f1or C, Garc\u00eda-Mart\u00ednez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60:174\u201382.","journal-title":"J Mol Evol"},{"key":"959_CR8","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1099\/mic.0.28048-0","volume":"151","author":"A Bolotin","year":"2005","unstructured":"Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. 2005;151:2551\u201361.","journal-title":"Microbiology"},{"key":"959_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.4161\/rna.23764","volume":"10","author":"SA Shah","year":"2013","unstructured":"Shah SA, Erdmann S, Mojica FJ, Garrett RA. Protospacer recognition motifs: mixed identities and functional diversity. RNA Biol. 2013;10:891\u20139.","journal-title":"RNA Biol"},{"key":"959_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1099\/mic.0.023960-0","volume":"155","author":"FJM Mojica","year":"2009","unstructured":"Mojica FJM, D\u00edez-Villase\u00f1or C, Garc\u00eda-Mart\u00ednez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology. 2009;155:733\u201340.","journal-title":"Microbiology"},{"key":"959_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature13011","volume":"507","author":"SH Sternberg","year":"2014","unstructured":"Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507:62\u20137.","journal-title":"Nature"},{"key":"959_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816\u201321.","journal-title":"Science"},{"key":"959_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrm1281","volume":"5","author":"MR Lieber","year":"2004","unstructured":"Lieber MR, Karanjawala ZE. Ageing, repetitive genomes and DNA damage. Nat Rev Mol Cell Biol. 2004;5:69\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"959_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576:149\u201357.","journal-title":"Nature"},{"key":"959_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fgene.2018.00021","volume":"9","author":"IG Matsoukas","year":"2018","unstructured":"Matsoukas IG. Commentary: programmable base editing of A.T to G.C in genomic DNA without DNA cleavage. Front Genet. 2018;9:21.","journal-title":"Front Genet"},{"key":"959_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533:420\u20134.","journal-title":"Nature"},{"key":"959_CR17","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1016\/j.ymthe.2024.07.017","volume":"32","author":"AR Yoon","year":"2024","unstructured":"Yoon AR, Lee S, Kim JH, Park Y, Koo T, Yun CO. CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer. Mol Ther. 2024;32:3618\u201328.","journal-title":"Mol Ther"},{"key":"959_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41587-019-0193-0","volume":"37","author":"BW Thuronyi","year":"2019","unstructured":"Thuronyi BW, Koblan LW, Levy JM, Yeh WH, Zheng C, Newby GA, et al. Continuous evolution of base editors with expanded target compatibility and improved activity. Nat Biotechnol. 2019;37:1070\u20139.","journal-title":"Nat Biotechnol"},{"key":"959_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41556-020-0471-6","volume":"22","author":"X Li","year":"2020","unstructured":"Li X, Qian X, Wang B, Xia Y, Zheng Y, Du L, et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol. 2020;22:282\u20138.","journal-title":"Nat Cell Biol"},{"key":"959_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41587-019-0236-6","volume":"37","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald J, Zhou R, Iyer S, Lareau CA, Garcia SP, Aryee MJ, et al. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol. 2019;37:1041\u20138.","journal-title":"Nat Biotechnol"},{"key":"959_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/hum.2024.043","volume":"35","author":"SY Hosseini","year":"2024","unstructured":"Hosseini SY, Mallick R, M\u00e4kinen P, Yl\u00e4-Herttuala S. Insights into prime editing technology: a deep dive into fundamentals, potentials, and challenges. Hum Gene Ther. 2024;35:649\u201368.","journal-title":"Hum Gene Ther"},{"key":"959_CR22","doi-asserted-by":"crossref","unstructured":"Abel EL, DiGiovanni J. Multistage carcinogenesis. In: Penning TM, editor. Chemical carcinogenesis. Totowa, NJ: Humana Press; 2011. p 27\u201351.","DOI":"10.1007\/978-1-61737-995-6_2"},{"key":"959_CR23","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.7150\/thno.42325","volume":"10","author":"Q Gao","year":"2020","unstructured":"Gao Q, Ouyang W, Kang B, Han X, Xiong Y, Ding R, et al. Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR\/Cas9 induces efficient tumor regression. Theranostics. 2020;10:5137\u201353.","journal-title":"Theranostics"},{"key":"959_CR24","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.ymthe.2020.07.003","volume":"28","author":"AR Yoon","year":"2020","unstructured":"Yoon AR, Jung BK, Choi E, Chung E, Hong J, Kim JS, et al. CRISPR-Cas12a with an oAd induces precise and cancer-specific genomic reprogramming of EGFR and efficient tumor regression. Mol Ther. 2020;28:2286\u201396.","journal-title":"Mol Ther"},{"key":"959_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11103-019-00871-5","volume":"100","author":"M Jiang","year":"2019","unstructured":"Jiang M, Hu H, Kai J, Traw MB, Yang S, Zhang X. Different knockout genotypes of OsIAA23 in rice using CRISPR\/Cas9 generating different phenotypes. Plant Mol Biol. 2019;100:467\u201379.","journal-title":"Plant Mol Biol"},{"key":"959_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18323-9","volume":"8","author":"Y Mizuno","year":"2018","unstructured":"Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, et al. DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. Sci Rep. 2018;8:106.","journal-title":"Sci Rep"},{"key":"959_CR27","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1093\/nar\/gkae098","volume":"52","author":"T Richl","year":"2024","unstructured":"Richl T, Kuper J, Kisker C. G-quadruplex-mediated genomic instability drives SNVs in cancer. Nucleic Acids Res. 2024;52:2198\u2013211.","journal-title":"Nucleic Acids Res"},{"key":"959_CR28","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-21-2519","volume":"82","author":"S Sayed","year":"2022","unstructured":"Sayed S, Sidorova OA, Hennig A, Augsburg M, Cortes Vesga CP, Abohawya M, et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing. Cancer Res. 2022;82:3002\u201315.","journal-title":"Cancer Res"},{"key":"959_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1097\/HEP.0000000000000700","volume":"79","author":"G Zhao","year":"2024","unstructured":"Zhao G, Ma Q, Yang H, Jiang H, Xu Q, Luo S, et al. Base editing of the mutated TERT promoter inhibits liver tumor growth. Hepatology. 2024;79:1310\u201323.","journal-title":"Hepatology"},{"key":"959_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.omtn.2022.09.005","volume":"30","author":"E Choi","year":"2022","unstructured":"Choi E, Hwang HY, Kwon E, Kim D, Koo T. Expanded targeting scope of LbCas12a variants allows editing of multiple oncogenic mutations. Mol Ther Nucleic Acids. 2022;30:131\u201342.","journal-title":"Mol Ther Nucleic Acids"},{"key":"959_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/nbt.3404","volume":"33","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. 2015;33:1293\u20138.","journal-title":"Nat Biotechnol"},{"key":"959_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","volume":"556","author":"JH Hu","year":"2018","unstructured":"Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556:57\u201363.","journal-title":"Nature"},{"key":"959_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s42003-023-05052-1","volume":"6","author":"G Jang","year":"2023","unstructured":"Jang G, Kweon J, Kim Y. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Commun Biol. 2023;6:681.","journal-title":"Commun Biol"},{"key":"959_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769\u201392.","journal-title":"Cancers"},{"key":"959_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"959_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015;54:709\u201335.","journal-title":"Clin Pharmacokinet"},{"key":"959_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/carcin\/bgr016","volume":"32","author":"H Sui","year":"2011","unstructured":"Sui H, Zhou S, Wang Y, Liu X, Zhou L, Yin P, et al. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63\/73 in colorectal cancer. Carcinogenesis. 2011;32:667\u201375.","journal-title":"Carcinogenesis"},{"key":"959_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin JJ. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharm Ther. 2023;249:108488.","journal-title":"Pharm Ther"},{"key":"959_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101065","volume":"73","author":"ZN Lei","year":"2024","unstructured":"Lei ZN, Albadari N, Teng QX, Rahman H, Wang JQ, Wu Z, et al. ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C. Drug Resist Updat. 2024;73. 101065.","journal-title":"Drug Resist Updat"},{"key":"959_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02194-6","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li L, Mendoza JJ, Wang D, Yan Q, Shi L, et al. Advances in A-to-I RNA editing in cancer. Mol Cancer. 2024;23:280.","journal-title":"Mol Cancer"},{"key":"959_CR41","doi-asserted-by":"crossref","unstructured":"Xu S, Zhou G, He Q, Ding J, Liu X, Cheng Y, et al. A-to-I-edited miR-1251-5p restrains tumor growth and metastasis in lung adenocarcinoma through regulating TCF7-mediated Wnt signaling pathway. Discov Oncol. 2024;15:587.","DOI":"10.1007\/s12672-024-01462-7"},{"key":"959_CR42","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41388-023-02673-y","volume":"42","author":"G Romano","year":"2023","unstructured":"Romano G, Le P, Nigita G, Saviana M, Micalo L, Lovat F, et al. A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells. Oncogene. 2023;42:1597\u2013606.","journal-title":"Oncogene"},{"key":"959_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. Science. 2017;358:1019\u201327.","journal-title":"Science"},{"key":"959_CR44","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu V, Sotillo E, Bjelajac JR, Chen C, Malipatlolla M, Guerrero JA, et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell. 2024;187:1278\u201395.e20.","journal-title":"Cell"},{"key":"959_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38588","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Han H. Strategies for improving the genome-editing efficiency of class 2 CRISPR\/Cas system. Heliyon. 2024;10:e38588.","journal-title":"Heliyon"},{"key":"959_CR46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.bbrc.2020.04.040","volume":"526","author":"J Cai","year":"2020","unstructured":"Cai J, Chen J, Wu T, Cheng Z, Tian Y, Pu C, et al. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in hepatocellular carcinoma. Biochem Biophys Res Commun. 2020;526:1170\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"959_CR47","doi-asserted-by":"crossref","unstructured":"Belli O, Karava K, Farouni R, Platt RJ. Multimodal scanning of genetic variants with base and prime editing. Nat Biotechnol. 2025;43:1458\u201370.","DOI":"10.1038\/s41587-024-02439-1"},{"key":"959_CR48","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","volume":"160","author":"S Chen","year":"2015","unstructured":"Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246\u201360.","journal-title":"Cell"},{"key":"959_CR49","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"959_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21:78.","journal-title":"Mol Cancer"},{"key":"959_CR51","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"959_CR52","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"959_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"959_CR54","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26:732\u201340.","journal-title":"Nat Med"},{"key":"959_CR55","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"959_CR56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","volume":"6","author":"SP Iyer","year":"2022","unstructured":"Iyer SP, Sica RA, Ho PJ, Hu B, Zain J, Prica A, et al. S262: The cobalt-lym Study Of Ctx130: a phase 1 dose escalation study Of Cd70-targeted allogeneic crispr-Cas9\u2013engineered Car T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies. HemaSphere. 2022;6:163\u20134.","journal-title":"HemaSphere"},{"key":"959_CR57","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27:2764\u201372.","journal-title":"Clin Cancer Res"},{"key":"959_CR58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140:619\u201329.","journal-title":"Blood"},{"key":"959_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389:899\u2013910.","journal-title":"N Engl J Med"},{"key":"959_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1288383","volume":"13","author":"R Chen","year":"2023","unstructured":"Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, et al. CAR-T treatment for cancer: prospects and challenges. Front Oncol. 2023;13:1288383.","journal-title":"Front Oncol"},{"key":"959_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05214-9","volume":"13","author":"TL Bonneaud","year":"2022","unstructured":"Bonneaud TL, Lefebvre CC, Nocquet L, Basseville A, Roul J, Weber H, et al. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death Dis. 2022;13:787.","journal-title":"Cell Death Dis"},{"key":"959_CR62","doi-asserted-by":"crossref","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5:e133977.","DOI":"10.1172\/jci.insight.133977"},{"key":"959_CR63","doi-asserted-by":"publisher","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641.","journal-title":"Oncoimmunology"},{"key":"959_CR64","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","volume":"42","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen X, Bao W, Liu G, Wei W, Ping Y. An oncolytic virus-T cell chimera for cancer immunotherapy. Nat Biotechnol. 2024;42:1876\u201387.","journal-title":"Nat Biotechnol"},{"key":"959_CR65","doi-asserted-by":"crossref","unstructured":"Gryciuk A, Rogalska M, Baran J, Kuryk L, Staniszewska M. Oncolytic adenoviruses armed with co-stimulatory molecules for cancer treatment. Cancers. 2023;15:1947.","DOI":"10.3390\/cancers15071947"},{"key":"959_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42490-019-0016-x","volume":"1","author":"J Hong","year":"2019","unstructured":"Hong J, Yun CO. Overcoming the limitations of locally administered oncolytic virotherapy. BMC Biomed Eng. 2019;1:17.","journal-title":"BMC Biomed Eng"},{"key":"959_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411032","volume":"12","author":"R Masarwy","year":"2025","unstructured":"Masarwy R, Breier D, Stotsky-Oterin L, Ad-El N, Qassem S, Naidu GS, et al. Targeted CRISPR\/Cas9 lipid nanoparticles elicit therapeutic genome editing in head and neck cancer. Adv Sci. 2025;12:e2411032.","journal-title":"Adv Sci"},{"key":"959_CR68","doi-asserted-by":"crossref","unstructured":"Bairqdar A, Karitskaya PE, Stepanov GA. Expanding horizons of CRISPR\/Cas technology: clinical advancements, therapeutic applications, and challenges in gene therapy. Int J Mol Sci. 2024;25:13321.","DOI":"10.3390\/ijms252413321"},{"key":"959_CR69","doi-asserted-by":"crossref","unstructured":"McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci Alliance. 2021;4:e202000875.","DOI":"10.26508\/lsa.202000875"},{"key":"959_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155785","volume":"266","author":"AK Balaraman","year":"2025","unstructured":"Balaraman AK, Babu MA, Moglad E, Mandaliya V, Rekha MM, Gupta S, et al. Exosome-mediated delivery of CRISPR-Cas9: A revolutionary approach to cancer gene editing. Pathol Res Pract. 2025;266:155785.","journal-title":"Pathol Res Pract"},{"key":"959_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00701-x","volume":"12","author":"E Di Carlo","year":"2024","unstructured":"Di Carlo E, Sorrentino C. State of the art CRISPR-based strategies for cancer diagnostics and treatment. Biomark Res. 2024;12:156.","journal-title":"Biomark Res"},{"key":"959_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13339","volume":"55","author":"J Han","year":"2022","unstructured":"Han J, Zhu L, Zhang J, Guo L, Sun X, Huang C, et al. Rational engineering of adeno-associated virus capsid enhances human hepatocyte tropism and reduces immunogenicity. Cell Prolif. 2022;55:e13339.","journal-title":"Cell Prolif"},{"key":"959_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201800494","volume":"5","author":"BR Lee","year":"2018","unstructured":"Lee BR, Jo E, Yoon HY, Yoon CJ, Lee HJ, Kwon KC, et al. Nonimmunogenetic viral capsid carrier with cancer targeting activity. Adv Sci. 2018;5:1800494.","journal-title":"Adv Sci"},{"key":"959_CR74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","volume":"60","author":"C Barnes","year":"2019","unstructured":"Barnes C, Scheideler O, Schaffer D. Engineering the AAV capsid to evade immune responses. Curr Opin Biotechnol. 2019;60:99\u2013103.","journal-title":"Curr Opin Biotechnol"},{"key":"959_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01925-5","volume":"23","author":"M Chehelgerdi","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23:9.","journal-title":"Mol Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00959-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:14Z","timestamp":1765753334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00959-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00959-9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}